ATE505455T1 - Als cb2-agonisten geeignete indolindanamidverbindungen und verfahren - Google Patents
Als cb2-agonisten geeignete indolindanamidverbindungen und verfahrenInfo
- Publication number
- ATE505455T1 ATE505455T1 AT08782233T AT08782233T ATE505455T1 AT E505455 T1 ATE505455 T1 AT E505455T1 AT 08782233 T AT08782233 T AT 08782233T AT 08782233 T AT08782233 T AT 08782233T AT E505455 T1 ATE505455 T1 AT E505455T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- agonists
- indolinanamide
- methods used
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- -1 Indole indane amides Chemical class 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95127507P | 2007-07-23 | 2007-07-23 | |
| US12/177,319 US7943658B2 (en) | 2007-07-23 | 2008-07-22 | Indole indane amide compounds useful as CB2 agonists and method |
| PCT/US2008/070810 WO2009015169A1 (en) | 2007-07-23 | 2008-07-23 | Indole indane amide compounds useful as cb2 agonists and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505455T1 true ATE505455T1 (de) | 2011-04-15 |
Family
ID=39720580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08782233T ATE505455T1 (de) | 2007-07-23 | 2008-07-23 | Als cb2-agonisten geeignete indolindanamidverbindungen und verfahren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7943658B2 (de) |
| EP (1) | EP2176221B1 (de) |
| JP (1) | JP2010534671A (de) |
| CN (1) | CN101778819A (de) |
| AT (1) | ATE505455T1 (de) |
| DE (1) | DE602008006200D1 (de) |
| WO (1) | WO2009015169A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083816A2 (de) * | 2006-10-27 | 2009-08-05 | Brystol-Myers Squibb Company | Heterocyclische amidverbindungen als kinasehemmer |
| TWI546537B (zh) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | 提供針對血液腫瘤之體外個人化藥物測試之方法 |
| WO2010141696A1 (en) * | 2009-06-04 | 2010-12-09 | Dara Biosciences, Inc. | Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives |
| IN2012DN02474A (de) | 2009-08-28 | 2015-08-21 | Arena Pharm Inc | |
| KR20130020881A (ko) | 2010-02-08 | 2013-03-04 | 알러간, 인코포레이티드 | 칸나비노이드-2 효능제로서 유용한 피리다진 유도체 |
| EP2582666B1 (de) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Arylsubstituierte indole und ihre verwendung als kalzium-kanal-blocker |
| RS55186B1 (sr) * | 2010-07-29 | 2017-01-31 | Astellas Pharma Inc | Kondenzovana jedinjenja piridina kao ligandi cb2 kanabinoidnog receptora |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EP2678330A1 (de) | 2011-02-25 | 2014-01-01 | Arena Pharmaceuticals, Inc. | Kristalline formen und verfahren zur herstellung von kondensierten azacyclen (cannabinoid-rezeptormodulatoren) |
| AU2012222149B2 (en) | 2011-02-25 | 2017-06-29 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| AR099336A1 (es) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| CN108794379A (zh) * | 2017-04-26 | 2018-11-13 | 华东师范大学 | 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用 |
| US20200078358A1 (en) | 2017-05-08 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds and Methods for Treatment of Visceral Pain |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3738393A (en) * | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
| US5552438A (en) * | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5401758A (en) * | 1993-10-07 | 1995-03-28 | Bristol-Myers Squibb Company | Pyridinyl cyanoguanidine compounds |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5998428A (en) * | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
| BR9607035A (pt) | 1995-02-13 | 1997-11-04 | Searle & Co | Isoxazois substituidos para o tratamento de inflamação |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| ATE233743T1 (de) | 1996-04-12 | 2003-03-15 | Searle & Co | N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren |
| IL127441A (en) | 1996-07-18 | 2003-02-12 | Merck Frosst Canada Inc | Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| DK1032575T3 (da) | 1997-09-05 | 2003-10-20 | Glaxo Group Ltd | 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor |
| SI1070056T1 (en) | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
| US7223772B1 (en) | 1998-11-03 | 2007-05-29 | Smithkline Beecham Corporation | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| ATE261444T1 (de) | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| US7115646B2 (en) * | 2003-10-08 | 2006-10-03 | Bristol Myers Squibb, Co. | Cyclic diamines and derivatives as factor Xa inhibitors |
| EP1848693A1 (de) | 2005-02-05 | 2007-10-31 | AstraZeneca AB | Indanamidderivate mit glykogenphosphorylase hemmender wirkung |
| TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
-
2008
- 2008-07-22 US US12/177,319 patent/US7943658B2/en active Active
- 2008-07-23 DE DE602008006200T patent/DE602008006200D1/de active Active
- 2008-07-23 AT AT08782233T patent/ATE505455T1/de not_active IP Right Cessation
- 2008-07-23 JP JP2010518343A patent/JP2010534671A/ja not_active Withdrawn
- 2008-07-23 EP EP08782233A patent/EP2176221B1/de not_active Not-in-force
- 2008-07-23 WO PCT/US2008/070810 patent/WO2009015169A1/en not_active Ceased
- 2008-07-23 CN CN200880103085A patent/CN101778819A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2176221B1 (de) | 2011-04-13 |
| US7943658B2 (en) | 2011-05-17 |
| WO2009015169A1 (en) | 2009-01-29 |
| JP2010534671A (ja) | 2010-11-11 |
| DE602008006200D1 (de) | 2011-05-26 |
| US20090041722A1 (en) | 2009-02-12 |
| EP2176221A1 (de) | 2010-04-21 |
| CN101778819A (zh) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE505455T1 (de) | Als cb2-agonisten geeignete indolindanamidverbindungen und verfahren | |
| UA112514C2 (uk) | АНТАГОНІСТИ C5aR | |
| NO20083011L (no) | Modulatorer av muskarine receptorer | |
| EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
| MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
| MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
| EA201171063A1 (ru) | Фармацевтические составы олмесартана | |
| EA200900403A1 (ru) | Соединения, которые модулируют рецептор св2 | |
| EA201100523A1 (ru) | Соединения сульфонила, которые селективно модулируют рецептор св2 | |
| UA99936C2 (en) | Biaryl substituted azabicyclic alkane derivatives | |
| EP2259679A4 (de) | Verfahren für die behandlung von kallikreinbedingten störungen | |
| EA200970818A1 (ru) | Гетероциклические соединения, содержащие их композиции и способы их применения | |
| EA201070238A1 (ru) | Соединения пиримидина | |
| BRPI0506679A (pt) | métodos de tratar osteoartrite com antagonistas de il-6 | |
| IL193479A0 (en) | Modulators of muscarinic receptors | |
| EA201200019A1 (ru) | Соединения, которые селективно модулируют рецептор св2 | |
| ATE477252T1 (de) | Substituierte diazepane als antagonisten an orexinrezeptoren | |
| NO20084006L (no) | Modulatorer av muskarinreseptorer | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| CY1119800T1 (el) | Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων | |
| DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
| NO20076344L (no) | Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren | |
| EA201171211A1 (ru) | Производные оксадиазола | |
| EP2493930A4 (de) | Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen | |
| BRPI0820440A2 (pt) | Inibidores aldh-2 no tratamento de desordens psiquiátricas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |